• No se han encontrado resultados

Breast - Cancer - Chemotherapy - Dissertations.

Metastatic breast cancer patients treated with low dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response

Metastatic breast cancer patients treated with low dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response

... 36. El-Arab LR, Swellam M, El Mahdy MM (2012) Metronomic chemotherapy in metastatic breast cancer: impact on VEGF. J Egypt Natl Canc Inst 24 (1):15-22. doi:10.1016/j.jnci.2011.12.002 37. Allegrini G, ...

25

Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients

Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients

... including breast cancer, at variance with COX-1, which is constitutively expressed in normal ...in breast cancer has been also associated with the presence of distant metastases ...in ...

27

Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy

Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy

... neoadjuvant chemotherapy were prospectively enrolled in this ...metastatic breast cancer (MBC) after PET-CT scan evaluation (Additional file ...

9

Predictive value of apoptosis, proliferation, HER 2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer

Predictive value of apoptosis, proliferation, HER 2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer

... of chemotherapy may target specific individual mole- cules that regulate these ...that breast cancer patients with tumors that overexpress HER-2 may derive more benefit from anthracycline-based ...

8

Association between baseline VEGF/sVEGFR 2 and VEGF/TSP 1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer

Association between baseline VEGF/sVEGFR 2 and VEGF/TSP 1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer

... Metronomic chemotherapy (MCT) with cyclophosphamide (Cy) and celecoxib (Cel) has therapeutic efficacy and low toxicity profile in advanced breast cancer patients (ABCP), but no reliable biomarkers of ...

7

Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

... of breast cancer, BL1, BL2, IM and M largely fall within the BLBC subtype, whereas LAR largely falls within the non-BLBC subtypes (Lehmann et al, 2011; Prat et al, 2013a; Mayer et al, ...

10

Título26,26,26,27,27,27 Hexadeuterated 1,25 Dihydroxyvitamin D3 (1,25D d6) As Adjuvant of Chemotherapy in Breast Cancer  Cell Lines

Título26,26,26,27,27,27 Hexadeuterated 1,25 Dihydroxyvitamin D3 (1,25D d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines

... as cancer [1–4]. In breast cancer 1,25D and some of its analogues inhibit cycle progression in MCF-7 human breast adenocarcinoma cells by arresting them in the G0/G1 phase ...human ...

12

How much survival benefit is necessary for breast cancer patients to opt for adjuvant chemotherapy? Results from a Chilean survey

How much survival benefit is necessary for breast cancer patients to opt for adjuvant chemotherapy? Results from a Chilean survey

... as chemotherapy, may remain reluctant to retrospectively visualise other options as ...receive chemotherapy would accept larger benefits than patients who received the treatment (p < ...tolerated ...

9

Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis

Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis

... including breast cancer ...in cancer cells leads to mitotic catastrophe and cell death from DNA damage due to the absence of G2-M arrest ...primary breast cancer, enhancing its bio- ...

9

Bone impact in breast cancer treatment

Bone impact in breast cancer treatment

... Breast cancer is one of the most frequent tumors in ...decade, breast cancer mortality has decreased by 6-8 ...with chemotherapy as well as hormonal treatment, either with estrogen ...

15

Anlisis de la efectividad de epirrubicina neoadyuvante de alta dosis al usar 4 vs  6 ciclos en pacientes  con cncer de mama localmente avanzado

Anlisis de la efectividad de epirrubicina neoadyuvante de alta dosis al usar 4 vs 6 ciclos en pacientes con cncer de mama localmente avanzado

... of breast cancer patients with complete pathologic primary tu- mor and axillary lymph node response to doxorubicin-based neoadjuvant ...operable breast cancer: nine-year results from the ...

9

Polimorfismos del gen MDR1 (ABCB1): efectos funcionales e implicaciones clnicas

Polimorfismos del gen MDR1 (ABCB1): efectos funcionales e implicaciones clnicas

... in this last study, they also found that 3435CC ca- rriers showed significantly increased drug response (OR: 1.82, 95% CI: 1.17-2.85), a difference that was only observed in Asians (OR: 1.97, 95% CI: 1.11-3.5). This ...

10

Biopsia de ganglio centinela despus de la administracin de quimioterapia neoadyuvante en pacientes con cncer de mama: un estudio piloto prospectivo

Biopsia de ganglio centinela despus de la administracin de quimioterapia neoadyuvante en pacientes con cncer de mama: un estudio piloto prospectivo

... vant chemotherapy for the treatment of breast cancer is still ...invasive breast cancer who received neoadjuvant chemotherapy underwent sentinel lymph node biopsy and complete ...

5

Efecto del immunepotent CRP en la respuesta clínica e inmunológica en pacientes con cáncer de mama.

Efecto del immunepotent CRP en la respuesta clínica e inmunológica en pacientes con cáncer de mama.

... in cancer therapy; it has been associated with improved quality of life during cancer ...of cancer, we investigated its clinical and immuno- logical effects as a therapy adjuvant on breast ...

82

Induccin cerebral de los genes de la ciclooxigenasa 2 por interleucina 1βdespes de quimioterapia

Induccin cerebral de los genes de la ciclooxigenasa 2 por interleucina 1βdespes de quimioterapia

... with cancer, five with chemotherapy and eight without ...of cancer treatment with or without chemotherapy with recent complete clinical information within three months of death through medical ...

5

Carcinoma of the breast occurring during pregnancy

Carcinoma of the breast occurring during pregnancy

... Both cases have evident clinical signs of mammar)' carcinoma with homo­ lateral axillary metastasis. In the first case, the tumor occupied the upper in­ ternal quadrant of the right breast; in the second, the ...

18

Endocrine disruptors as ligands of breast cancer proteins

Endocrine disruptors as ligands of breast cancer proteins

... This thesis was conceived to explore the plausibility of endocrine disruptors to affect the signaling related to breast cancer through protein-ligand interactions. Interestingly, we found that these ...

175

Familial Breast Cancer in Costa Rica: An initial approach

Familial Breast Cancer in Costa Rica: An initial approach

... with breast cancer by biopsy at an early age (before the age of fifty) each family should have at least three cases of female breast cancer, ovarian cancer, male breast ...

6

Estudio de adherencia y seguridad en pacientes a tratamiento con capecitabina

Estudio de adherencia y seguridad en pacientes a tratamiento con capecitabina

... (breast cancer, colorectal cancer, gas- tric cancer, off-label), adherence (tablet count, Morisky test, Sackett test), safety (assessment of adverse events, clinical evaluation by the ...

18

La cronoterapia en el tratamiento de enfermedades oncológicas

La cronoterapia en el tratamiento de enfermedades oncológicas

... Introduction: Both the human being as the cells that constituyed it, have biological clocks, which are influenced by internal and external factors that surround them, showing fluctuations thorught out a day. Said ...

40

Show all 1469 documents...

Related subjects